Wearable Injectors and Connected Devices Conference 2019

SMi Group9 - 10 October 2019, London, UK.
SMi is proud to present the inaugural Wearable Injectors and Connected Devices Conference, taking place in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

With this in mind, the conference will explore new technologies and advances of on-body devices for the administration of viscous and large molecule drug delivery, and evaluate the impact of IoT, connectivity and enhancement of user-interface, which make up core components within the wearable devices field.

Benefits of Attending

  • Listen to case studies from leading pharmaceutical companies revolutionising the medical device industry
  • Hear how on-body injectors are facilitating the administration of time-dependent, large volume and viscous drug delivery
  • Assess how connectivity is being used to improve patient adherence, health-monitoring and enhancing the user-interface
  • Explore the compatibility, pain and patient handling considerations projecting wearable devices as the future of drug delivery

Join Wearable Injectors and Connected Devices Conference 2019 in October 2019 to have the opportunity to network with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Plus two interactive pre-conference workshops

Tuesday 8th October 2019

Cross company collaboration to develop digital therapeutic solutions using connected devices

Workshop Leader: Digby Harris, Global Category Manager - Digital Therapeutics & Devices, AstraZeneca

Wearable injectors: Envisioning their evolution to address current and future unmet needs

Workshop Leader: James Blakemore, Senior Consultant, Cambridge Consultants
Workshop Leader: Sergio Marlorni, Senior Consultant, Cambridge Consultants

Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers of: Drug-delivery developers, Autoinjectors, Device Engineering, Human Factor, Scientist, Product, Injectables, Packaging, Regulatory Affairs, Connectivity, Medical Device Data, Novel Product Technology, Smart device developers, Training device developers, Device-safety solution providers, Drug developers or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceutical, biotech and solution providers.

To register please visit: www.wearable-injectors.co.uk/wpnwl

Early-Bird Rates

  • Book by 31st May and save £400
  • Book by 28th June and save £300
  • Book by 30th August and save £200

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...